604 / 1835
The paradigm for study design….
R-CHOP
R-CHOP+X
DLBCL
R
Biological and
clinical
stratification
Ongoing X=
Lenalidomide
Ibrutinib
Bortezomib
Brentuximab
everolimus
More to come…
Can we practically
deliver this design in
phase III with so many
agents?